<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0012">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Hernandez</surname>
    <given-names>J. J.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Pryszlak</surname>
    <given-names>M.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Smith</surname>
    <given-names>L.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Yanchus</surname>
    <given-names>C.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kurji</surname>
    <given-names>N.</given-names>
   </name>, 
   <name name-style="western">
    <surname>Shahani</surname>
    <given-names>V. M.</given-names>
   </name>, &amp; 
   <name name-style="western">
    <surname>Molinski</surname>
    <given-names>S. V.</given-names>
   </name>
  </person-group> (
  <year>2017</year>). 
  <article-title>Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics</article-title>. 
  <source>
   <italic>Frontiers in Oncology</italic>
  </source>, 
  <volume>7</volume>, 
  <fpage>273</fpage>
  <pub-id pub-id-type="doi">10.3389/fonc.2017.00273</pub-id>
  <pub-id pub-id-type="pmid">29184849</pub-id>
 </mixed-citation>
</ref>
